Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 12 of 12 results for canagliflozin

  1. Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

    Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    25 June 2014
    View recommendations

    Sections for TA315

  2. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

    Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    25 May 2016
    View recommendations

    Sections for TA390

  3. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

    Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    27 March 2019
    View recommendations

    Sections for TA572

  4. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

    Technology appraisal guidance
    Published
    25 March 2015
    View recommendations

    Sections for TA336

  5. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    5 June 2019
    View recommendations

    Sections for TA583

  6. Dapagliflozin for treating chronic kidney disease (TA775)

    Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults.

    Technology appraisal guidance
    Published
    9 March 2022
    View recommendations

    Sections for TA775

  7. Type 2 diabetes in adults: management (NG28)

    This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

    NICE guideline
    Last updated
    29 June 2022
    View recommendations

    Sections for NG28

  8. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  9. Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888

    Awaiting development [GID-TA11377] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

    In development [GID-TA10555] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA418

  12. Insulin icodec for treating type 2 diabetes [ID6175]

    In development [GID-TA11104] Expected publication date: TBC

    Technology appraisal guidance
    In development